- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dimethyl Fumarate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis
- Interventions
- dimethyl fumarate, montelukast, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 50
- States / cities
- Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Multiple Sclerosis
- Interventions
- Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
- Other
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Tecfidera, Teriflunomide
- Interventions
- Dimethyl Fumarate, Teriflunomide
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multiple Sclerosis, Exposure During Pregnancy
- Interventions
- Dimethyl fumarate, Peginterferon beta-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- ALKS 8700
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 74
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Tysabri
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 80,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BG00012, Placebo, Glatiramer Acetate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Tecfidera, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 7 more
- Conditions
- Healthy
- Interventions
- dimethyl fumarate - Reference form, dimethyl fumarate - Test form
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Evansville, Indiana
- Conditions
- Multiple Sclerosis (MS) Relapsing Remitting
- Interventions
- Vumerity, Tecfidera
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 38
- States / cities
- Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
- Conditions
- Systemic Sclerosis, Pulmonary; Hypertension
- Interventions
- Dimethyl Fumarate (DMF), Placebo Oral Tablet
- Drug
- Lead sponsor
- Robert Lafyatis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Simethicone, Loperamide, Peanut Butter
- Drug · Other
- Lead sponsor
- Rocky Mountain MS Research Group, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Sclerosis
- Interventions
- Tecfidera
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Interventions
- Dimethyl Fumarate, Temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- natalizumab, dimethyl fumarate
- Biological · Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more